Head to Head Review: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 4.6% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Neuphoria Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Neuphoria Therapeutics and Immunic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	1	2	0	2.25
Immunic	1	0	5	3	3.11

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 362.56%. Immunic has a consensus target price of $6.00, indicating a potential upside of 440.54%. Given Immunic’s stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Neuphoria Therapeutics.

Valuation & Earnings

This table compares Neuphoria Therapeutics and Immunic”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	1.56	-$370,000.00	($4.42)	-1.03
Immunic	N/A	N/A	-$97.17 million	($0.70)	-1.59

Neuphoria Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neuphoria Therapeutics and Immunic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-25.98%	-18.39%
Immunic	N/A	-1,197.81%	-264.95%

Summary

Immunic beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.